Archive for 29 enero 2007

Panópticos

enero 29, 2007

El panóptico es un sistema de vigilancia diseñado por Bentham, a cuya implementación

nos vamos acercando rápidamente.

Los sistemas de video callejero (no casualmente ubicados en los sitios donde hay habitualmente manifestaciones de protesta), los registros de todas nuestras operaciones bancarias, de crédito, etc, y los biobancos (voluntarios o no), a los que se van incorporando lentamente los datos – no de los condenados, ni siquiera de los procesados – de los meramente “detenidos” por la policía, forman parte de este complejo de vigilancia del ciudadano.

 

Duerma tranquilo, SU Gobierno (lo) vigila.

LJ

Miente, miente (y oculta), que algo quedará

enero 29, 2007

BBC NEWS

Drug company ‘hid’ suicide link

Secret e-mails reveal that the UK’s biggest drug company distorted trial results of an anti-depressant, covering up a link with suicide in teenagers.

Panorama reveals that GlaxoSmithKline (GSK) attempted to show that Seroxat worked for depressed children despite failed clinical trials.

And that GSK-employed ghostwriters influenced ‘independent’ academics.

GSK told Panorama: “GSK utterly rejects any suggestion that it has improperly withheld drug trial information.”

GSK faces action in the US where bereaved families have joined together to sue the company.

As a result, GSK has been forced to open its confidential internal archive.

Karen Barth Menzies is a partner in one of the firms representing many of the families.

She has examined thousands of the documents which are stored, box upon box, in an apartment in Malibu, California.

She said: “Even when they have negative studies that show that this drug Seroxat is going to harm some kids they still spin that study as remarkably effective and safe for children.”

GSK’s biggest clinical trial of Seroxat on children was held in the US in the 1990s and called Study 329.

Child psychiatrist Dr Neal Ryan of the University of Pittsburgh was paid by GSK as a co-author of Study 329.

In 2002 he also gave a talk on childhood depression at a medical conference sponsored by GSK.

He said that Seroxat could be a suitable treatment for children and later told Panorama reporter Shelley Jofre that it probably lowered rather than raised suicide rates.

In amongst the archive of emails in Malibu, Shelley was surprised to find that her own emails to Dr Ryan from 2002 asking questions about the safety of Seroxat had been forwarded to GSK asking for advice on how to respond to her.

She also found an email from a public relations executive working for GSK which said: “Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results. Essentially the study did not really show it was effective in treating adolescent depression, which is not something we want to publicise.”

But the article was published in the Journal of the American Academy of Child and Adolescent Psychiatry which says it ranks as number one in child mental health in the world.

The editor in chief of the British Medical Journal, Fiona Godlee, said that what she calls the “blind-eye culture of medicine” should be exposed by professionals.

She has written in response to the Panorama film: “We shouldn’t have to rely on investigative journalists to ask the difficult questions.

“Reputations for sale are reputations at risk. We need to make that risk so high it’s not worth taking.”

Bereaved families in the UK cannot get legal aid to sue GSK.

The Medicine and Healthcare Products Regulatory Authority (MHRA) began a criminal investigation into GSK three years ago but no action has been taken yet.

A spokesperson told Panorama that the investigation has been given substantial addional resources and remains a high priority.

Seroxat was banned for under 18s in 2003 after the MHRA, revealed that GSK’s own studies showed the drug actually trebles the risk of suicidal thoughts and behaviour in depressed children.

  • Secrets of the Drug Trials will be broadcast on Monday 29 January at 2030 on BBC One and this site.
  • If you are affected by any of the issues in the programme and would like to talk to someone in confidence for further information and support, please call the BBC Action Line on 0800 077 077. Lines open at 2100 GMT on Monday 29 January for a week and may be busy but the Action Line will be open from 0730 GMT until 0000 GMT. All calls are free and confidential.
  • Story from BBC NEWS:
    http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/6308871.stm
    Published: 2007/01/29 07:35:07 GMT
    © BBC MMVII

    ¿Desde donde visitan este blog?

    enero 28, 2007

    Como blog llamado Bioética Latinoamericana estamos muy satisfechos con la procedencia de los visitantes. Esto se puede ver en los dos gráficos siguientes, amable y gratuitamente provistos por http://www.sitemeter.com/, que mantiene una estadística de los visitantes del blog.

     

    Si bien esperamos que en un futuro aumente el porcentaje de visitantes de los distintos países de América Latina, esta distribución muestra claramente que estamos llegando adonde nos propusimos.

    LJ

    Para reflexionar antes de reanudar Doha

    enero 27, 2007

    Medecins Sans Frontiers

    PEOPLE BEFORE PATENTS:
    THE LIVES OF MILLIONS ARE AT STAKE!!

    SIGN-ON TO HELP PROTECT ACCESS TO AFFORDABLE MEDICINES!!

    Pharmaceutical company Novartis is taking the Indian government to court. If the company wins, millions of people across the globe could have their sources of affordable medicines dry up.

    Novartis was one of the 39 companies that took the South African government to court five years ago, in an effort to overturn the country’s medicines act that was designed to bring drug prices down. Now Novartis is up to it again and is targeting India.

    India produces affordable medicines that are vital to many people living in developing countries. Over half the medicines currently used for AIDS treatment in developing countries come from India and such medicines are used to treat over 80% of the 80,000 AIDS patients in Médecins Sans Frontières projects.

    If Novartis is successful in its challenge against the Indian government and its patent law, more medicines are likely to be patented in India, making it very difficult for generic producers to make affordable versions of them. This could affect millions of people around the world who depend on medicines produced in India.

    Tell Novartis it has no business standing in the way of people’s right to access the medicines they need. Sign on and urge Novartis to DROP THE CASE against the Indian government.

    SIGN MSF’S ‘DROP THE CASE’ PETITION

    Millions of people around the world today rely on affordable medicines produced in India.  India’s law contains elements that help put people before patents, but Novartis is taking the Indian government to court to force a change in the law. Neither Novartis, nor any company, should stand in the way of people’s right to access the medicines they need. 
    We urge Novartis to DROP THE CASE now against the Indian government.
    People before Patents: The lives of millions are at stake!

    Para firmar ir a: http://www.msf.org/petition_india/international.html

    LJ

    De regreso

    enero 27, 2007

    Luego de un mes de reposo del blog henos aquí de vuelta con novedades varias.

    – Para quienes estén interesados hay una nueva lista de correo y debate: biolatina@googlegroups.com.
    Se puede acceder a ella para enviar y recibir mails, intercambiar ideas, publicar noticias, etc.
    No es una lista censurada y hay espacio para todo pensamiento sea de derecha o izquierda, religioso o agnóstico o ateo,
    del Norte o del Sur, capitalista o socialista, físico o metafísico.

    Lo único que pedimos es respeto por todas las ideas publicadas.

    – Quienes deseen recibir por mail la noticia de nuevos posts pueden ir a la columna de la derecha, abajo, justo arriba de Site Meter, donde dice “Actualizar por e- mail”. Haciendo click allí se puede uno suscribir y recibir los nuevos posts por e-mail.

    – Hay agregados en la columna de la derecha, tales como links a blogs de bioética. Quienes tengan blogs sobre el tema (propios o conocidos), por favor envíenlos y serán agregados a la lista.

    – Hemos renovado el aspecto agregando a un lanzador de flores con cierto aspecto de piquetero. Quizás se podría explorar la idea de “piquetes florales” o “lanzadores de ideas”, como maneras de resistencia y aguante.

    Desde mañana nuevos posts.

    Un saludo con abrazo latinoamericano y, como siempre, esperamos sus críticas, comentarios y aportes.

    LJ